Pulmonary Embolism Therapeutics Market Research Report By Treatment Type (Anticoagulants, Thrombolytics, Mechanical Thrombectomy), By Patient Population (Patients With Symptomatic Pulmonary Embolism, Patients With Asymptomatic Pulmonary Embolism, Patients With High-Risk Pulmonary Embolism), By Drug Route of Administration (Intravenous, Subcutaneous, Oral), By Drug Type (Direct Oral Anticoagulants (DOACs), Heparins, Vitamin K Antagonists), By End-Use Sector (Hospitals, Clinics, Ambulatory Surgical Centers) and By Regional (North America, Eur

Pulmonary Embolism Therapeutics Market Overview

As per MRFR analysis, the Pulmonary Embolism Therapeutics Market Size was estimated at 1.07 (USD Billion) in 2022. The Pulmonary Embolism Therapeutics Market Industry is expected to grow from 1.13(USD Billion) in 2023 to 1.9 (USD Billion) by 2032. The Pulmonary Embolism Therapeutics Market CAGR (growth rate) is expected to be around 5.92% during the forecast period (2024 - 2032).

Key Pulmonary Embolism Therapeutics Market Trends Highlighted

The Pulmonary Embolism Therapeutics Market is projected to be driven by increasing prevalence of pulmonary embolism. Rising incidence of deep venous thrombosis, obesity, and sedentary lifestyle are major factors contributing to the growth of the market. Additionally, advancements in diagnostic techniques and the introduction of novel therapeutics are expected to offer lucrative opportunities for market expansion. Recent trends indicate a shift towards anticoagulants with better safety profiles, as well as the emergence of new oral anticoagulants that offer improved convenience and reduced need for monitoring. The market is also expected to benefit from growing awareness about pulmonary embolism and the availability of reimbursement policies that cover treatment costs.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Pulmonary Embolism Therapeutics Market Drivers

Rising Prevalence of Pulmonary Embolism

Pulmonary embolism is a health condition where one or more arteries in the lungs are blocked by a clot of blood. It is a highly dangerous condition that might end fatally. The incidence of this condition is increasing globally due to the aging population, rising rates of obesity, as well as patients who are kept in hospitals and using more medical devices. Hence, as the number of patients with pulmonary embolism increases, the demand for its corresponding treatment will increase.

Technological Advancements in Pulmonary Embolism Therapeutics

The Pulmonary Embolism Therapeutics Market Industry is constantly evolving, with new and innovative treatments being developed all the time. Some of the most promising recent advancements include the development of new anticoagulants, thrombolytics and surgical techniques. These advancements are improving the outcomes of patients with PE and reducing the risk of complications.

Growing Awareness of Pulmonary Embolism

Pulmonary embolism is a serious condition, but it is often underdiagnosed and undertreated. This is due to a lack of awareness of the condition among both patients and healthcare professionals. However, there is a growing awareness of PE, thanks to public health campaigns and educational programs. As awareness of PE increases, so too will the demand for effective treatments.

Pulmonary Embolism Therapeutics Market Segment Insights:

Pulmonary Embolism Therapeutics Market Treatment Type Insights

The Pulmonary Embolism Therapeutics Market is classified by Treatment Type as Anticoagulants, Thrombolytics, and Mechanical Thrombectomy. The Anticoagulants segment held the major share in the market of the Pulmonary Embolism Therapeutics Market as they are predominantly used as a first-line treatment to prevent and treat pulmonary embolism due to their high efficiency and effectiveness. The Anticoagulants market is expected to dominate the market in the forecast period as well due to the rise in the prevalence of thromboembolic disorders and the new drugs developed related to anticoagulants.Thrombolytics, which are used to dissolve blood clots, are the second most proficient treatment for pulmonary embolism. Though it consists of side effects those are liable for the serious consequences. Hence, it is anticipated to grow at a lower rate. The mechanical Thrombectomy treatment option is considered a maiden treatment option to remove clots developed in the lungs, and it is predicted to dominate the market over the next few years. The growth of the Pulmonary Embolism Therapeutics Market is primarily due to the rise in the prevalence of thromboembolic disorders and the product advancement and the development of new treatments that facilitate providing higher efficacy.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Pulmonary Embolism Therapeutics Market Patient Population Insights

The Pulmonary Embolism Therapeutics Market is segmented by patient population into patients with symptomatic pulmonary embolism, patients with asymptomatic pulmonary embolism, and patients with high-risk pulmonary embolism. Patients with Symptomatic Pulmonary Embolism Patients with symptomatic pulmonary embolism experience the following symptoms: chest pain, shortness of breath and cough. These patients are at a higher risk of developing complications, such as deep vein thrombosis and death. Patients with asymptomatic pulmonary embolism do not experience any symptoms.These patients are usually diagnosed with pulmonary embolism after a medical test is performed, such as a chest X-ray or CT scan. Patients with High-Risk Pulmonary Embolism These patients have a higher risk of developing complications, such as DVT and death. They are usually treated with anticoagulants, such as warfarin or unfractionated heparin. The Pulmonary Embolism Therapeutics Market for patients with high-risk pulmonary embolism is expected to reach USD 1.9 billion by 2032, growing at a CAGR of 5.92%.

Pulmonary Embolism Therapeutics Market Drug Route of Administration Insights

Intravenous, subcutaneous, and oral routes of administration dominate the pulmonary embolism therapeutics market. Intravenous administration accounts for the largest share due to the rapid onset of action and high bioavailability. Subcutaneous administration provides sustained drug release and is preferred for long-term therapy. Oral administration is gaining popularity due to its convenience and cost-effectiveness. The global parenteral PE therapeutics market is anticipated to expand at a CAGR of 5.6% during 2023-2032. The growth of the market is primarily attributed to the increasing prevalence of pulmonary embolism, the rising demand for minimally invasive procedures, and the introduction of novel anticoagulants and thrombolytics.

Pulmonary Embolism Therapeutics Market Drug Type Insights

The Pulmonary Embolism Therapeutics Market is segmented by drug type into Direct Oral Anticoagulants (DOACs), Heparins and Vitamin K Antagonists. Among these segments, DOACs are expected to hold the largest market share in 2023, owing to their ease of administration, predictable anticoagulant effect, and reduced risk of bleeding compared to traditional anticoagulants. Heparins are also widely used in the treatment of pulmonary embolism, particularly in patients with renal impairment or those requiring rapid anticoagulation. Vitamin K Antagonists, such as warfarin, have been used historically for the treatment of pulmonary embolism but are being increasingly replaced by DOACs due to their narrow therapeutic index and the need for frequent monitoring.

Pulmonary Embolism Therapeutics Market End-Use Sector Insights

The end-use sector segmentation of the Pulmonary Embolism Therapeutics Market comprises Hospitals, Clinics and Ambulatory Surgical Centers. Hospitals dominate the market due to the high prevalence of pulmonary embolism cases, advanced infrastructure, and the availability of specialized healthcare professionals. The increasing number of hospital admissions for pulmonary embolism treatment is a key driver of market growth. Clinics hold a significant market share, primarily due to the rising preference for outpatient care and the growing number of specialized clinics offering comprehensive pulmonary embolism diagnosis and treatment services.Ambulatory Surgical Centers are gaining traction as they provide cost-effective and convenient care for less severe pulmonary embolism cases. The growing demand for minimally invasive procedures and the increasing number of ASCs are fueling the growth of this segment.

Pulmonary Embolism Therapeutics Market Regional Insights

The regional landscape of the Pulmonary Embolism Therapeutics Market is characterized by diverse market dynamics and growth patterns. North America commands a significant share of the global market, driven by advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and favorable reimbursement policies. In 2023, the regional market was valued at USD 556 million and is projected to reach USD 820 million by 2032, exhibiting a CAGR of 5.5%. Europe follows North America in terms of market share, with a sizable market size of USD 360 million in 2023.The region is expected to witness steady growth, supported by increasing awareness about pulmonary embolism and the availability of advanced treatment options. The Asia Pacific (APAC) region is poised for robust growth, driven by rising healthcare expenditure, growing awareness and the presence of a large patient population. South America and the Middle East and Africa (MEA) regions are expected to contribute to the overall market growth, albeit at a slower pace compared to other regions.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Pulmonary Embolism Therapeutics Market Key Players And Competitive Insights:

The industry of the Pulmonary Embolism Therapeutics Market is highly competitive, and there are several leading players in the field. The major companies that form the context of the market and that make the market dynamic include Bayer AG, Bristol-Myers Squibb Company, Boehringer Ingelheim, Merck Co., Inc., and Pfizer Inc. All of these companies take an active part in research and development, launch their products, and cooperate strategically. The industry also involves many emerging players that concentrate on the development of new and cost-competitive forms of therapy.

In the next few years, the competitive landscape of the Pulmonary Embolism Therapeutics Market industry is expected to remain very dynamic and competitive, and these tendencies will be caused by the evolution of new technology and by the increasing propensity of pulmonary embolism.Bayer AG is a leading pharmaceutical company and one of the leading players in the Pulmonary Embolism Therapeutics Market. Bayer AG provides a variety of anticoagulants and antiplatelet agents in the sector, and the effectiveness of these products is currently being tested due to the numerous clinical trials.

Bayer AG’s competitive advantage may be defined by the company’s wide sales and distribution network as well as by its broad range of markets in which the company operates. The company also has strong financial performance and a great reputation in the market, as their products are well-known to customers worldwide.Pfizer Inc. is another example of a large company that operates in the Pulmonary Embolism Therapeutics Market. Pfizer Inc. specializes in providing anticoagulants and thrombolytics as part of the treatment of pulmonary embolism. They support their production with a wide marketing and sales network that promotes the medication among medical professionals and patients. The company’s competitive advantage is determined by their good financial performance and large sales network.

Key Companies in the Pulmonary Embolism Therapeutics Market Include:

• LEO Pharma


• Thrombogenics


• Apotex


• Boehringer Ingelheim


• Actavis


• Sanofi


• Janssen Pharmaceuticals


• BristolMyers Squibb


• Pfizer


• Bayer


• Takeda Pharmaceutical Company


• Novartis


• Mylan


• Daiichi Sankyo


• Teva Pharmaceutical Industries

Pulmonary Embolism Therapeutics Market Industry Developments

The Pulmonary Embolism Therapeutics Market is anticipated to witness steady growth between 2024 and 2032, with a CAGR of 5.92%. In 2023, the market is estimated to be valued at approximately USD 1.13 billion, and by 2032, it is projected to reach USD 1.9 billion. Key factors driving market growth include the rising prevalence of pulmonary embolism, increasing awareness of the condition, and the introduction of novel therapeutic options. The market is also witnessing increasing adoption of direct oral anticoagulants (DOACs) due to their convenience and efficacy. However, factors such as high treatment costs and potential side effects of certain therapies may restrain market growth to some extent. Recent advancements in the field include the development of catheter-directed therapies and the exploration of gene therapy approaches for pulmonary embolism treatment. Overall, the market is poised for moderate growth in the coming years.

Pulmonary Embolism Therapeutics Market Segmentation Insights

• Anticoagulants


• Thrombolytics


• Mechanical Thrombectomy

• Patients With Symptomatic Pulmonary Embolism


• Patients With Asymptomatic Pulmonary Embolism


• Patients With High-Risk Pulmonary Embolism

• Intravenous


• Subcutaneous


• Oral

• Direct Oral Anticoagulants (DOACs)


• Heparins


• Vitamin K Antagonists

• Hospitals


• Clinics


• Ambulatory Surgical Centers

Pulmonary Embolism Therapeutics Market Regional Outlook

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa